Datapoint: Libtayo Scores Second Skin Cancer Nod

The FDA last week approved Regeneron Pharmaceuticals, Inc. and Sanofi’s Libtayo for the treatment of advanced basal cell carcinoma (BCC) that has not responded to previous treatment in some patients. The anti-PD-1 inhibitor is the first immunotherapy drug approved to treat BCC. Libtayo was approved for the treatment of metastatic cutaneous squamous cell carcinoma in September 2018, and currently holds preferred placement under the pharmacy benefit for 9% of all covered lives. Libtayo is not covered for 21% of lives.

SOURCE: MMIT Analytics, as of 2/11/21

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 26

Datapoint: Appeals Court Upholds Kentucky Medicaid Awards

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 22

Datapoint: Highmark Launching New Primary Care Initiative in Pittsburgh

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 21

Datapoint: Novartis Asks FDA to Stave Off Early Entresto Copies

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today